Publicacións nas que colabora con Pablo Villoslada (20)

2019

  1. Axonal and Myelin Neuroprotection by the Peptoid BN201 in Brain Inflammation

    Neurotherapeutics, Vol. 16, Núm. 3, pp. 808-827

2017

  1. Erratum: The disruption of mitochondrial axonal transport is an early event in neuroinflammation. [J Neuroinflammation., 12, 1, (2015)(152)] DOI: 10.1186/s12974-015-0375-8

    Journal of Neuroinflammation

2016

  1. First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases

    Science Translational Medicine, Vol. 8, Núm. 370

2015

  1. The disruption of mitochondrial axonal transport is an early event in neuroinflammation

    Journal of Neuroinflammation, Vol. 12, Núm. 1

2014

  1. Differential neuroprotective effects of 5′-deoxy-5′- methylthioadenosine

    PLoS ONE, Vol. 9, Núm. 3

  2. Dynamic molecular monitoring of retina inflammation by in vivo Raman spectroscopy coupled with multivariate analysis

    Journal of Biophotonics, Vol. 7, Núm. 9, pp. 724-734

  3. Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis

    PLoS ONE, Vol. 9, Núm. 12

2013

  1. Dynamic cross-regulation of antigen-specific effector and regulatory T cell subpopulations and microglia in brain autoimmunity

    BMC Systems Biology, Vol. 7

  2. Oxidative Stress and Proinflammatory Cytokines Contribute to Demyelination and Axonal Damage in a Cerebellar Culture Model of Neuroinflammation

    PLoS ONE, Vol. 8, Núm. 2

2012

  1. Guidelines on the appropriate use of animal models for developing therapies in multiple sclerosis

    Revista de Neurologia, Vol. 54, Núm. 2, pp. 114-124

  2. Neuroprotective therapies for multiple sclerosis

    European Neurological Review, Vol. 7, Núm. 3, pp. 189-195

2011

  1. Animal models of multiple sclerosis

    Multiple Sclerosis: A New Paradigm (Nova Science Publishers, Inc.), pp. 37-68

  2. Systemic inflammation induces axon injury during brain inflammation

    Annals of Neurology, Vol. 70, Núm. 6, pp. 932-942

2010

  1. Preclinical studies of methylthioadenosine for the treatment of multiple sclerosis

    Multiple Sclerosis, Vol. 16, Núm. 9, pp. 1102-1108

2008

  1. HLA-DR2 and white matter lesion distribution in MS

    Journal of Neuroimaging, Vol. 18, Núm. 3, pp. 328-331

  2. IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis

    European Journal of Immunology, Vol. 38, Núm. 2, pp. 576-586

  3. Immunotherapy for neurological diseases

    Clinical Immunology

2007

  1. A network analysis of the human T-cell activation gene network identifies Jagged1 as a therapeutic target for autoimmune diseases

    PLoS ONE, Vol. 2, Núm. 11

  2. Therapeutic opportunities for trophic factors in brain inflammation

    Current Pharmaceutical Analysis, Vol. 3, Núm. 1, pp. 7-15

2006

  1. Methylthioadenosine reverses brain autoimmune disease

    Annals of Neurology, Vol. 60, Núm. 3, pp. 323-334